Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis

Steroids

Volumn 76, Issue 9, 2011, Pages 885-891

  Lu, Changxue ^a   Cheng, Sheue Yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinogenesis; Extranuclear signaling; Mouse model; Thyroid cancer; Thyroid hormone receptor mutants; Thyroid hormone receptors

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ALPHA INTEGRIN; BETA INTEGRIN; FIBRONECTIN; FOCAL ADHESION KINASE; GELATINASE B; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; THYROID HORMONE RECEPTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

ANAPLASTIC THYROID CARCINOMA; BASEMENT MEMBRANE; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CYTOSKELETON; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSDUCTION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER CANCER; LUNG CANCER; METASTASIS; ONCOGENE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THYROID CANCER; THYROID CARCINOGENESIS; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR CELL; WESTERN BLOTTING;

ANIMALS; CELL ADHESION MOLECULES; CELL MOVEMENT; EXTRACELLULAR MATRIX; FRAMESHIFT MUTATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTANT PROTEINS; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; THYROID HORMONE RECEPTORS BETA; THYROID NEOPLASMS;

MUS;

EID: 79959898331     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.03.016     Document Type: Review

References (52)

1. Cheng SY. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 2000;1:9-18.
2. Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 2003;213:1-11. (Pubitemid 38229150)
3. O'Shea PJ, Williams GR. Insight into the physiological actions of thyroid hormone receptors from genetically modified mice. J Endocrinol 2002;175:553-70. (Pubitemid 36054228)
4. O'Malley BW, Kumar R. Nuclear receptor coregulators in cancer biology. Cancer Res 2009;69:8217-22.
5. Lin KH, Shieh HY, Chen SL, Hsu HC. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 1999;26:53-61.
6. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J. Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 2002;87:1120-8. (Pubitemid 36121076)
7. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 2002;23:25-33. (Pubitemid 34213548)
8. Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 2001;86:5572-6. (Pubitemid 33070290)
9. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA, et al. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci U S A 2000;97:13209-14.
10. Suzuki H, Willingham MC, Cheng SY. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002;12:963-9. (Pubitemid 35404130)
11. Weiss RE, Refetoff S. Resistance to thyroid hormone. Rev Endocr Metab Disord 2000;1:97-108.
12. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD. Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest 1991;88:2123-30.
13. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, et al. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 2006;25:2736-47.
14. Furuya F, Hanover JA, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A 2006;103:1780-5. (Pubitemid 43228770)
15. Furuya F, Lu C, Willingham MC, Cheng SY. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007;28:2451-8. (Pubitemid 350238946)
16. Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY, et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 2005;146:4456-63. (Pubitemid 41324044)
17. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 2008;28:4598-608. (Pubitemid 351977757)
18. Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA, et al. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest 2006;116:2972-84. (Pubitemid 44684482)
19. Zimonjic DB, Kato Y, Ying H, Popescu NC, Cheng SY. Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice. Cancer Genet Cytogenet 2005;161:104-9. (Pubitemid 41133475)
20. Humphries MJ. Integrin structure. Biochem Soc Trans 2000;28:311-39.
21. Fong YC, Hsu SF, Wu CL, Li TM, Kao ST, Tsai FJ, et al. Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer 2009;64:13-21.
22. Somanath PR, Kandel ES, Hay N, Byzova TV. Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly. J Biol Chem 2007;282:22964-76. (Pubitemid 47267339)
23. Hattar R, Maller O, McDaniel S, Hansen KC, Hedman KJ, Lyons TR, et al. Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res 2009;11:R5.
24. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 2002;277:21352-60. (Pubitemid 34952275)
25. Jin Y-J, Park I, Hong I-K, Byun H-J, Choi J, Kim Y-M, et al. Fibronectin and vitronectin induce AP-1-mediated matrix metalloproteinase-9 expression through integrin [alpha]5[beta]1/[alpha]v[beta]3-dependent Akt, ERK and JNK signaling pathways in human umbilical vein endothelial cells. Cell Signal 2011;23:125-34.
26. Noh TW, Soung YH, Kim HI, Gil HJ, Kim JM, Lee EJ, et al. Effect of {beta}4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma. Anticancer Res 2010;30:4485-92.
27. Kitajiri S, Hosaka N, Hiraumi H, Hirose T, Ikehara S. Increased expression of integrin beta-4 in papillary thyroid carcinoma with gross lymph node metastasis. Pathol Int 2002;52:438-41. (Pubitemid 34989300)
28. Ensinger C, Obrist P, Bacher-Stier C, Mikuz G, Moncayo R, Riccabona G. beta 1-Integrin expression in papillary thyroid carcinoma. Anticancer Res 1998;18:33-40. (Pubitemid 28174681)
29. Hoffmann S, Maschuw K, Hassan I, Reckzeh B, Wunderlich A, Lingelbach S, et al. Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines. Thyroid 2005;15:1011-20. (Pubitemid 41475711)
30. Lu C, Zhao L, Ying H, Willingham MC, Cheng SY. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology 2010;151:1929-39.
31. Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008;8:427-32.
32. Schlaepfer DD, Hunter T. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol 1996;16:5623-33. (Pubitemid 26315082)
33. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68. (Pubitemid 40064899)
34. Angers-Loustau A, Hering R, Werbowetski TE, Kaplan DR, Del Maestro RF. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2004;2:595-605. (Pubitemid 39557663)
35. Avizienyte E, Keppler M, Sandilands E, Brunton VG, Winder SJ, Ng T, et al. An active Src kinase-beta-actin association is linked to actin dynamics at the periphery of colon cancer cells. Exp Cell Res 2007;313:3175-88. (Pubitemid 47299092)
36. Kanchanawong P, Shtengel G, Pasapera AM, Ramko EB, Davidson MW, Hess HF, et al. Nanoscale architecture of integrin-based cell adhesions. Nature 2010;468:580-4.
37. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10:175-81. (Pubitemid 38524888)
38. Pechkovsky DV, Scaffidi AK, Hackett TL, Ballard J, Shaheen F, Thompson PJ, et al. Transforming growth factor beta1 induces alphavbeta3 integrin expression in human lung fibroblasts via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway. J Biol Chem 2008;283:12898-908.
39. Lee SH, Lee YJ, Park SW, Kim HS, Han HJ. Caveolin-1 and integrin beta1 regulate embryonic stem cell proliferation via p38 MAPK and FAK in high glucose. J Cell Physiol 2010, doi:10.1002/jcp.22510.
40. Sullivan RJ, Atkins MB. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Expert Opin Investig Drugs 2010;19:1205-16.
41. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003;22:395-403. (Pubitemid 36791895)
42. Kwon SM, Kim SA, Yoon JH, Ahn SG. Transforming growth factor beta1-induced heat shock protein 27 activation promotes migration of mouse dental papilla-derived MDPC-23 cells. J Endod 2010;36:1332-5.
43. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009;94:2199-203.
44. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008;68:1935-44. (Pubitemid 351416580)
45. Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 2009;297:E1238-46.
46. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005;146:2864-71. (Pubitemid 41002793)
47. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 2011;51:99-115.
48. Leonard JL. Non-genomic actions of thyroid hormone in brain development. Steroids 2008;73:1008-12.
49. Farwell AP, Lynch RM, Okulicz WC, Comi AM, Leonard JL. The actin cytoskeleton mediates the hormonally regulated translocation of type II iodothyronine 5′-deiodinase in astrocytes. J Biol Chem 1990;265:18546-53.
50. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010;31:139-70.
51. Teodorczyk M, Martin-Villalba A. Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol 2010;222:1-10.
52. Guigon CJ, Fozzatti L, Lu C, Willingham MC, Cheng SY. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis 2010;31:1284-91.